Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 28, Issue 6, Pages 596-602Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881113517955
Keywords
Obsessive-compulsive disorder; treatment; medication; augmentation; international; effectiveness
Funding
- Canadian Foundation for Innovation (CFI)
- Forest Laboratories
- Janssen-Ortho Inc.
- National Institutes of Health
- Pfizer Inc.
- Servier
- Wyeth-Ayerst
- Astra Zeneca
- Biovail
- Eli Lilly
- Labo Pharm
- Lundbeck
- Shire
- International College of Obsessive Compulsive Spectrum Disorders
- UKMRC
- European College of Neuropsychopharmacology
- Intermational College of Behavioural Addiction
- Transcept
- Roche
- Forest
- IP-oxytocin
- Otsuka
- Pfizer
- Pferin
- Abbott
- Astrazeneca
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Johnson Johnson
- Orion
- Pharmacia
- Solvay
- Sumitomo
- Takeda
- Tikvah
- Wyeth
- National Institute of Mental Health
- Department of Defense
Ask authors/readers for more resources
Objective: It is unknown what next-step strategies are being used in clinical practice for patients with obsessive-compulsive disorder (OCD) who do not respond to first-line treatment. As part of a cross-sectional study of OCD, treatment and symptom information was collected. Method: Consecutive OCD out-patients in nine international centers were evaluated by self-report measures and clinical/ structured interviews. OCD symptom severity was evaluated by the Yale Brown Obsessive Compulsive Scale (YBOCS) and Clinical Global Impression-Severity Scale (CGI-S). Clinical response to current treatment was evaluated by the CGI-Improvement Scale (CGI-I <= 2). Results: In total, 361 participants reported taking medication; 77.6% were taking a selective serotonin reuptake inhibitor; 50% reported use of at least one augmentation strategy. Antipsychotics were most often prescribed as augmenters (30.3%), followed by benzodiazepines (24.9%) and antidepressants (21.9%). No differences in OCD symptom severity were found between patients taking different classes of augmentation agents. Conclusions: Results from this international cross-sectional study indicate that current OCD treatment is in line with evidence-based treatment guidelines. Although augmentation strategies are widely used, no significant differences in OCD symptom severity were found between monotherapy and augmentation or between different therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available